Navigation Links
The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
Date:6/1/2009

DOYLESTOWN, Pa. June 1 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that IVS Associates, Inc., the inspector of election for Quigley's 2009 annual meeting of shareholders, issued its final report, showing that Ted Karkus' seven director nominees received a larger number of votes than Quigley's incumbent directors.

The Company also announced that despite the final voting results issued today by IVS, the final outcome of the director election remains uncertain. On May 19, 2009, one day before the Company's 2009 Annual Meeting, the Company announced it had uncovered an undisclosed financial arrangement between Karkus and the Company's Quigley Pharma, Inc. subsidiary COO, Dr. Richard A. Rosenbloom. Karkus had previously stated in sworn testimony that at no time did he have any financial arrangement with any employee of The Quigley Corporation. Since the Annual Meeting, the Company has learned that Dr. Rosenbloom may have also had undisclosed financial arrangements with one of Karkus' director nominees and with John Ligums, an alleged member of the Karkus Group.

On May 29, 2009, upon a motion by the Company detailing these recent developments, the District Court Judge in the United States District Court for the Eastern District of Pennsylvania ordered the Company to operate under a standstill agreement with respect to the composition of the Company's Board of Directors pending a Court hearing on the motion. The Company expects the motion will be heard by Friday, June 5, 2009.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY,

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
2. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
3. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
4. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
5. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
6. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
7. The Quigley Corporation Reports First Quarter 2009 Results
8. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
9. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
10. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
11. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 In Pretrial Order #139 (Scheduling ... discovery conferences would be beneficial in this [MDL].” Accordingly, ... “At the end of December,” the order further provides, ... additional conferences. , “The plain import of this ... still much to be discussed as these cases progress ...
(Date:9/17/2014)... Dennis Thompson HealthDay ... -- Exposure in the womb to household chemicals known ... developing asthma, Columbia University researchers reported in a new ... risk of developing asthma between age 5 and 11 ... levels of two phthalates (pronounced thal-ates), the researchers found. ...
(Date:9/17/2014)... Scripps Research Institute (TSRI) have devised a new ... against vancomycin-resistant strains of MRSA and other disease-causing ... have not one but two distinct mechanisms of ... resistance quickly. , "This is the prototype of ... clinical use a generation or maybe even two ...
(Date:9/17/2014)... York, New York (PRWEB) September 17, 2014 ... filings involving the Conserve line of metal-on-metal hip ... now underway in U.S. District Court, Northern District ... an updated Case List issued by the U.S. ... 2014, at least 397 product liability claims have ...
(Date:9/17/2014)... Toledo, Ohio (PRWEB) September 17, 2014 ... hearing for today, September 17, 2014, to consider: , ... Testosterone Replacement Therapy (TRT), and, 2. ... of TRT. , With the TRT litigation ongoing, an ... FDA on the dangers of testosterone replacement therapy. Among ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2
... From June Dairy Month through,the State Fair, summer ... June 1, Minnesotans will be able get details about ... mouse. ExploreDairy.com is a,one-stop resource for all the latest ... hardworking dairy farm families., ExploreDairy.com is designed to ...
... 29 The following is a,statement by Matthew L. ... Health Organization,s World No Tobacco Day, to be celebrated,May ... of the global,tobacco epidemic and the urgent need for ... save lives., This year,s theme -- Tobacco-Free Youth: ...
... May 29 The Academy of General,Dentistry (AGD) expresses ... reauthorize the Dental Health Improvement Act (S,3067) for another ... and Benjamin Cardin (D-MD). The intent of the Act ... shortage of dental health,professionals., "Last week was a ...
... Leaders of Indiana and Purdue universities Thursday ... Translational Sciences Institute (CTSI), a medical research initiative ... business and government to swiftly transform discoveries into ... National Institutes of Health has awarded a five-year ...
... The Musculoskeletal Transplant,Foundation (MTF) will provide military hospitals ... joint repair for injured servicemen and,women., Military ... obtaining,tissue used for cartilage transplantation and meniscus grafts ... types of tissue are in high,demand for U.S. ...
... NY) The National Institutes of Health has ... University and Montefiore Medical Center one of its ... million over five years. The grant will support ... Research (ICTR), whose overarching goal is to collaboratively ...
Cached Medicine News:Health News:ExploreDairy.com Debuts With Information on Minnesota Dairy Events, People and Products 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 3Health News:AGD Thanks Senators for Introducing Bill to Reauthorize the Dental Health Improvement Act 2Health News:NIH awards Einstein College of Medicine & Montefiore Medical Center $22M grant 2Health News:NIH awards Einstein College of Medicine & Montefiore Medical Center $22M grant 3
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
(Date:9/17/2014)... Sept. 17, 2014 Isis Pharmaceuticals, Inc. ... has earned a $4 million milestone payment from ... with the initiation of a Phase 3 study ... (MDR), gram-negative bacterial infections.  The Phase 3 study ... the efficacy and safety of plazomicin compared to ...
(Date:9/17/2014)... FRANCISCO , Sept. 17, 2014 Sutro ... bispecific antibodies, and the biopharmaceutical division of Merck KGaA, ... EMD Serono in the United States ... a collaboration and license agreement to develop antibody drug ... to a cytotoxic drug. The antibody is thought to ...
Breaking Medicine Technology:New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... The Board of Directors of Stereotaxis, Inc. (NASDAQ: ... that it reaffirmed the Company,s plans for both the launch ... Odyssey ™  platform into standard labs. "At ... commercial strategies put forth for the launch of Epoch, as ...
... 2011 Reportlinker.com announces that a new market ... Pharmaceutical Manufacturers - India ... This register contains information about 1327 ... includes the following details of the manufacturers: ...
Cached Medicine Technology:Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 2Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 3
... High Prevalence of Sleep Disordered Breathing (SDB) ... As Prevalent as Diabetes, with Vast Majority ... common form of SDB, affects an estimated ... Only 5% of the OSA patients ...
... The layout is designed efficiently for ... are configured for maximum efficiency. It ... It can be set-up in ... any mobile modality pad and it ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
Medicine Products: